Community-acquired pneumonia in chronic obstructive pulmonary disease.
Journal
Current opinion in infectious diseases
ISSN: 1473-6527
Titre abrégé: Curr Opin Infect Dis
Pays: United States
ID NLM: 8809878
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
pubmed:
6
2
2020
medline:
1
5
2021
entrez:
6
2
2020
Statut:
ppublish
Résumé
The aim of this study was to discuss the literature on community-acquired pneumonia (CAP) in patients with chronic obstructive pulmonary disease (COPD). Well designed studies show that COPD is the strongest risk factor for development of CAP. Lung microbiome, abnormal lung immunity and pathogen virulence are important components of the pathogenesis of CAP in COPD. The cause of CAP in patients with COPD is similar to that of non-COPD patients. However, patients with COPD are at an increased risk of infection by Gram-negative bacilli, including Pseudomonas aeruginosa. Empiric treatment regimens for CAP in COPD should contemplate the most common pathogens, and consideration should be given for the coverage of Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus depending on the severity of CAP, severity of COPD or prior isolation of these pathogens. COPD has not been consistently shown to be an independent risk factor for worse short-term outcomes in patients with CAP. In a long-term study, COPD is associated with worse outcomes in these patients. Research focused on lung microbiome and abnormal lug immunity in patients with COPD should be prioritized. Further clinical research should try to consolidate the role of additional treatment approaches such as immunomodulating medications in COPD patients with CAP.
Identifiants
pubmed: 32022741
doi: 10.1097/QCO.0000000000000639
pii: 00001432-202004000-00011
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
173-181Références
Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009; 64: (Suppl 3): iii1–iii55.
Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2095–2128.
Ramirez JA, Wiemken TL, Peyrani P, et al. Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality. Clin Infect Dis 2017; 65:1806–1812.
Arnold FW, Wiemken TL, Peyrani P, et al. Mortality differences among hospitalized patients with community-acquired pneumonia in three world regions: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. Respir Med 2013; 107:1101–1111.
Cavallazzi R, Wiemken T, Arnold FW, et al. Outcomes in patients with community-acquired pneumonia admitted to the intensive care unit. Respir Med 2015; 109:743–750.
Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. Am J Respir Crit Care Med 2017; 195:557–582.
GBD., 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study. Lancet Respir Med 2017; 5:691–706.
Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 386:743–800.
Jackson ML, Neuzil KM, Thompson WW, et al. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis 2004; 39:1642–1650.
Bordon J, Slomka M, Gupta R, et al. University of Louisville Pneumonia Study Group. Hospitalization due to community-acquired pneumonia in patients with chronic obstructive pulmonary disease: incidence, epidemiology and outcomes. Clin Microbiol Infect 2019; 26:220–226.
de Miguel-Diez J, Lopez-de-Andres A, Hernandez-Barrera V, et al. Impact of COPD on outcomes in hospitalized patients with community-acquired pneumonia: analysis of the Spanish national hospital discharge database (2004–2013). Eur J Intern Med 2017; 43:69–76.
Mullerova H, Chigbo C, Hagan GW, et al. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med 2012; 106:1124–1133.
Williams NP, Coombs NA, Johnson MJ, et al. Seasonality, risk factors and burden of community-acquired pneumonia in COPD patients: a population database study using linked healthcare records. Int J Chron Obstruct Pulmon Dis 2017; 12:313–322.
Lin SH, Ji BC, Shih YM, et al. Comorbid pulmonary disease and risk of community-acquired pneumonia in COPD patients. Int J Tuberc Lung Dis 2013; 17:1638–1644.
Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356:775–789.
Drummond MB, Dasenbrook EC, Pitz MW, et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008; 300:2407–2416.
Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014; 3:CD010115.
Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007; 176:162–166.
Cavallazzi R, Singh S. Inhaled corticosteroids in chronic obstructive pulmonary disease: how significant is the risk of pneumonia and should it impact use of inhaled corticosteroids? Curr Infect Dis Rep 2011; 13:296–301.
Pavord ID, Lettis S, Locantore N, et al. Blood eosinophils and inhaled corticosteroid/long-acting beta-2 agonist efficacy in COPD. Thorax 2016; 71:118–125.
Dickson RP, Huffnagle GB. The lung microbiome: new principles for respiratory bacteriology in health and disease. PLoS Pathog 2015; 11:e1004923.
Ramirez JA, Cavallazzi R. Community-acquired pneumonia pathogenesis in patients with chronic obstructive pulmonary disease. J Respir Infect 2019; 3:2.
Dickson RP, Erb-Downward JR, Prescott HC, et al. Cell-associated bacteria in the human lung microbiome. Microbiome 2014; 2:28.
O’Dwyer DN, Dickson RP, Moore BB. The lung microbiome, immunity, and the pathogenesis of chronic lung disease. J Immunol 2016; 196:4839–4847.
Lambrecht BN. Alveolar macrophage in the driver's seat. Immunity 2006; 24:366–368.
Wright JR. Host defense functions of pulmonary surfactant. Biol Neonate 2004; 85:326–332.
Zenewicz LA. Oxygen levels and immunological studies. Front Immunol 2017; 8:324.
Pifarre R, Falguera M, Vicente-de-Vera C, Nogues A. Characteristics of community-acquired pneumonia in patients with chronic obstructive pulmonary disease. Respir Med 2007; 101:2139–2144.
Dai RX, Kong QH, Mao B, et al. The mortality risk factor of community acquired pneumonia patients with chronic obstructive pulmonary disease: a retrospective cohort study. BMC Pulm Med 2018; 18:12.
Bonnesen B, Baunbaek Egelund G, Vestergaard Jensen A, et al. Is chronic obstructive pulmonary disease a risk factor for death in patients with community acquired pneumonia? Infect Dis (Lond) 2019; 51:340–347.
Liapikou A, Polverino E, Ewig S, et al. Severity and outcomes of hospitalised community-acquired pneumonia in COPD patients. Eur Respir J 2012; 39:855–861.
Braeken DC, Franssen FM, von Baum H, et al. Bacterial aetiology and mortality in COPD patients with CAP: results from the German Competence Network, CAPNETZ. Int J Tuberc Lung Dis 2017; 21:236–243.
Huang WC, Lee CH, Wu MF, et al. Clinical features, bacteriology of endotracheal aspirates and treatment outcomes of patients with chronic obstructive pulmonary disease and community-acquired pneumonia in an intensive care unit in Taiwan with an emphasis on eosinophilia versus noneosinophilia: a retrospective case-control study. BMJ Open 2018; 8:e020341.
Restrepo MI, Babu BL, Reyes LF, et al. Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients. Eur Respir J 2018; 52:pii: 1701190.
Gomez-Junyent J, Garcia-Vidal C, Viasus D, et al. Clinical features, etiology and outcomes of community-acquired pneumonia in patients with chronic obstructive pulmonary disease. PLoS One 2014; 9:e105854.
Sahuquillo-Arce JM, Menendez R, Mendez R, et al. Age-related risk factors for bacterial aetiology in community-acquired pneumonia. Respirology 2016; 21:1472–1479.
Burk M, El-Kersh K, Saad M, et al. Viral infection in community-acquired pneumonia: a systematic review and meta-analysis. Eur Respir Rev 2016; 25:178–188.
Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 2019; 200:e45–e67.
Cavallazzi R, Ramirez JA. Influenza and viral pneumonia. Clin Chest Med 2018; 39:703–721.
Osadnik CR, Tee VS, Carson-Chahhoud KV, et al. Noninvasive ventilation for the management of acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2017; 7:CD004104.
Murad A, Li PZ, Dial S, Shahin J. The role of noninvasive positive pressure ventilation in community-acquired pneumonia. J Crit Care 2015; 30:49–54.
Carrillo A, Gonzalez-Diaz G, Ferrer M, et al. Noninvasive ventilation in community-acquired pneumonia and severe acute respiratory failure. Intensive Care Med 2012; 38:458–466.
Walters JA, Tan DJ, White CJ, et al. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014; CD001288.
Torres A, Sibila O, Ferrer M, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA 2015; 313:677–686.
Cavallazzi R, Ramirez JA. Using steroids in patients with community-acquired pneumonia at the University of Louisville Hospital: who, what, and when. J Respir Infect 2017; 1:4.
Restrepo MI, Mortensen EM, Pugh JA, Anzueto A. COPD is associated with increased mortality in patients with community-acquired pneumonia. Eur Respir J 2006; 28:346–351.
Molinos L, Clemente MG, Miranda B, et al. Community-acquired pneumonia in patients with and without chronic obstructive pulmonary disease. J Infect 2009; 58:417–424.
Dusemund F, Chronis J, Baty F, et al. The outcome of community-acquired pneumonia in patients with chronic lung disease: a case-control study. Swiss Med Wkly 2014; 144:w14013.
Walters JA, Tang JN, Poole P, Wood-Baker R. Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2017; 1:CD001390.
Centers for Disease Control, Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012; 61:816–819.
Matanock A, Lee G, Gierke R, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged >/ = 65 years: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2019; 68:1069–1075.
Grijalva CG, Zhu Y, Williams DJ, et al. Association between hospitalization with community-acquired laboratory-confirmed influenza pneumonia and prior receipt of influenza vaccination. JAMA 2015; 314:1488–1497.
Foster DA, Talsma A, Furumoto-Dawson A, et al. Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly. Am J Epidemiol 1992; 136:296–307.
Grohskopf LA, Alyanak E, Broder KR, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices - United States, 2019–20 Influenza Season. MMWR Recomm Rep 2019; 68:1–21.